D.E. Shaw & Co
RUBY

D.E. Shaw & Co’s Rubius Therapeutics, Inc RUBY Stock Holding History

D.E. Shaw & Co’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,000
Closed -$488K – 5418
2021
Q2 		$488K Sell
20,000
-30,000
-60% -$750K ﹤0.01% 4047
2021
Q1 		$1.32M Buy
+50,000
New +$730K ﹤0.01% 2896

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co's RUBY Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 117,446 shares — an estimated $100K sold.

D.E. Shaw & Co first reported a position in RUBY in Q2 2020 and held it in 9 quarters. The position peaked at $4.47M in Q1 2021. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 117,446 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $100K.
  • D.E. Shaw & Co first reported a position in Rubius Therapeutics, Inc in Q2 2020 and held it in 9 quarters.
  • D.E. Shaw & Co's Rubius Therapeutics, Inc position peaked at $4.47M in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.